Table 1 .
2016 WHO LYMPHOMA CLASSIFICATION | TOTAL OF CASES | CLL | HL | DLBCL, NOS | BL | SMZL | ENMZL | B-LBL | AITL | FL | LPL |
|---|---|---|---|---|---|---|---|---|---|---|---|
Number (%) | 66 | 23 (34.8) | 17 (25.8) | 14 (21.2) | 5 (7.6) | 2 (3) | 1 (1.5) | 1 (1.5) | 1 (1.5) | 1 (1.5) | 1 (1.5) |
Gender (%) | M = 44 (66.7%) F = 22 (33.3%) | 12 (18.18) 11 (16.6) | 13 (19.7) 4 (6) | 9 (13.6) 5 (7.5) | 4 (6) 1 (1.5) | 1 (1.5) 1 (1.5) | 1 (1.5) 0 | 1 (1.5) 0 | 1 (1.5) 0 | 1 (1.5) 0 | 1 (1.5) 0 |
M: F (p = 0.295) | 2:1 | 1.1:1 | 3.3:1 | 1.8:1 | 4:1 | 1:1 | M | M | M | M | M |
Age Age range Mean age (p = 0.574) | 2–85 yrs. 44.1 yrs | 36–78 yrs. 55.7 yrs | 4–64 yrs. 33.8 yrs | 7–85 yrs. 46.1 yrs. | 7–65 yrs. 27.6 yrs | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Nodal (%) | 55 (83.3%) | 19 (34.5) | 17 (30.9) | 12 (21.8) | 4 (7.3) | 0 | 0 | 1 (1.8) | 1 (1.8) | 1 (1.8) | 0 |
Extranodal (%) | 11 (16.7%) | 4 (36.4) | 0 | 2 (18.2) | 1 (9.1) | 2 (18.2) | 1 (9.1) | 0 | 0 | 0 | 1 (9.1) |
EBV (%) (p = 0.023) | 10 (1.5%) | 0 | 6 (60) | 1 (10) | 3 (30) | 0 | 0 | 0 | 0 | 0 | 0 |